Across TCGA pan-cancer cohorts, MIR3920 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MIR3920’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where MIR3920 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR3920 is over-expressed in tumor.
LUAD are the cancer types where MIR3920 tumor–normal differential expression is most reproducible.